Ibrutinib

Results: 7



#Item
1Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM Pa

Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM Pa

Add to Reading List

Source URL: www.bcshguidelines.com

Language: English - Date: 2015-07-22 04:38:28
2Ontwikkeling van nieuwe anti-kankermedicijnen geïllustreerd adhv Ibrutinib (Imbruvica) ter behandeling van B-cel maligniteiten, o.a. chronische lymfatische leukemie (CLL) en mantelcellymfoom (MCL) Marcel Spaargaren

Ontwikkeling van nieuwe anti-kankermedicijnen geïllustreerd adhv Ibrutinib (Imbruvica) ter behandeling van B-cel maligniteiten, o.a. chronische lymfatische leukemie (CLL) en mantelcellymfoom (MCL) Marcel Spaargaren

Add to Reading List

Source URL: www.lymmcare.nl

Language: Dutch - Date: 2014-11-17 05:53:19
    3Ibrutinib (Imbruvica) for Waldenström’s macroglobulinaemia

    Ibrutinib (Imbruvica) for Waldenström’s macroglobulinaemia

    Add to Reading List

    Source URL: www.hsc.nihr.ac.uk

    Language: English
      4Contains Nonbinding Recommendations Draft Guidance on Ibrutinib This draft guidance, once finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or co

      Contains Nonbinding Recommendations Draft Guidance on Ibrutinib This draft guidance, once finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or co

      Add to Reading List

      Source URL: www.fda.gov

      Language: English
      5 pERC deliberated upon the cost effectiveness of ibrutinib compared with a treatment mix reflecting different local standards of care and noted there is currently no single standard of care in Canada in this clinical s

      pERC deliberated upon the cost effectiveness of ibrutinib compared with a treatment mix reflecting different local standards of care and noted there is currently no single standard of care in Canada in this clinical s

      Add to Reading List

      Source URL: www.pcodr.ca

      Language: English - Date: 2015-01-09 16:28:10
      6IMBRUVICATM (ibrutinib) capsules

      IMBRUVICATM (ibrutinib) capsules

      Add to Reading List

      Source URL: www.accessdata.fda.gov

      Language: English - Date: 2013-11-13 13:13:53
      7HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. IMBRUVICATM (ibrutinib) capsules,

      HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. IMBRUVICATM (ibrutinib) capsules,

      Add to Reading List

      Source URL: www.accessdata.fda.gov

      Language: English - Date: 2014-02-13 12:51:13